MAPK3 and neoplasm: Therefore, the lack in tumour remission after trastuzumab administration may be explained by (i) increased AKT/PKB phosphorylation, (ii) a rapid increase in AKT/PKB mRNA and protein synthesis and (iii) a lack of ERK1/2 dephosphorylation.